Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW590735 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | PLACEBO_COMPARATOR | Placebo |
| Arm 2 | ACTIVE_COMPARATOR | Fenofibrate |
| Name | Type | Description |
|---|---|---|
| GW590735 | DRUG | 1µg to 20µg daily doses of GW590735 |
| fenofibrate | DRUG | Marketed Drug |
Inclusion criteria: * High-density lipoprotein cholesterol less than or equal to 45 mg/dL. * Triglycerides greater than or equal to 120 mg/dL and less than or equal to 500 mg/dL. * Women must be surgically sterile or postmenopausal. Exclusion criteria: * Heart disease * Diabetes
GW590735 is an investigational small molecule being developed for the treatment of dyslipidaemias, a group of conditions characterized by abnormal levels of lipids in the blood. It is intended to address cardiovascular risk by improving lipid profiles, including increasing 'good cholesterol' (HDL) levels, as indicated in its clinical trial.
GW590735 is a small molecule, but its specific molecular target has not been disclosed in the available information. The drug is being studied for its effects on lipid metabolism in patients with dyslipidaemias, with a focus on raising high-density lipoprotein (HDL) cholesterol levels.
GW590735 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with dyslipidaemias.
GW590735 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study involving 250 participants with dyslipidaemias. The drug remains investigational and has not been approved by regulatory authorities.
GW590735 has one completed clinical trial registered under NCT00169559, titled 'Dyslipidemia Study Investigating The Increase In Good Cholesterol'. This Phase 2 study enrolled 250 participants with dyslipidaemias across the United States and Canada, and was randomized, double-blind, and placebo-controlled.
No alternative names for GW590735 have been identified. The drug is known solely by its code name GW590735 in clinical and research contexts. It is a distinct investigational compound being developed by GSK plc for the treatment of dyslipidaemias.